Grace Therapeutics, Inc. 8K

Grace Therapeutics filed a corporate presentation detailing its plan to address a CMC-based FDA Complete Response Letter for GTx-104 via a dual-source manufacturing strategy and NDA resubmission, along with clinical data, commercialization plans, IP, and capitalization.

Grace Therapeutics, Inc. furnished a late-summer 2026 corporate presentation as an exhibit, outlining its strategy to resubmit the New Drug Application for its lead candidate GTx-104—an intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage—after receiving FDA Type A meeting minutes clarifying that the Complete Response Letter related solely to CMC and manufacturing (cGMP compliance at its current CDMO and additional leachables/excipient data) rather than clinical safety or efficacy, and describing a dual-source manufacturing and additional non-clinical work plan, Phase 3 STRIVE-ON trial outcomes, commercialization strategy, intellectual property protection, capital structure, and the status of deprioritized programs GTx-102 and GTx-101.

Filing Facts

CIK

1444192

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-029837

Alert Tier

6